Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins

European Journal of Neurology

Volumn 13, Issue 12, 2006, Pages 1359-1363

  Trebst, C ^a   Brunhorn, K ^a   Lindner, M ^a,b   Windhagen, A ^a   Stangel, M ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

Author keywords

Chemokine receptors; Immune mediated neuropathies; Immunoglobulin for intravenous use

Indexed keywords

CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR3; IMMUNOGLOBULIN;

ADULT; AGED; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GUILLAIN BARRE SYNDROME; HEART FAILURE; HUMAN; IMMUNOMODULATION; LYMPHOCYTE HOMING; LYMPHOID ORGAN; MALE; MOTOR NEUROPATHY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

ADULT; AGED; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DIABETIC NEUROPATHIES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECEPTORS, CHEMOKINE;

EID: 33750963275     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2006.01521.x     Document Type: Article

References (19)

1. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001; 56: 445-449.
2. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996; 119: 1067-1077.
3. Hughes RA. Plasma exchange versus intravenous immunoglobulin for Guillain-Barre syndrome. Therapeutic Apheresis 1997; 1: 129-130.
4. Ransohoff RM. The chemokine system in neuroinflammation: an update. Journal of Infectious Diseases 2002; 186: S152-S156.
5. Feng L. Role of chemokines in inflammation and immunoregulation. Immunologic Research 2000; 21: 203-210.
6. Kivisäkk P, Liu Z, Trebst C, et al. Flow cytometric analysis of chemokine receptor expression on cerebrospinal fluid leukocytes. Methods 2003; 29: 319-325.
7. Kim CH, Nagata K, Butcher EC. Dendritic cells support sequential reprogramming of chemoattractant receptor profiles during naive to effector T cell differentiation. Journal of Immunology 2003; 171: 152-158.
8. Campbell DJ, Kim CH, Butcher EC. Chemokines in the systemic organization of immunity. Immunological Reviews 2003; 195: 58-71.
9. Kivisäkk P, Trebst C, Lee JC, et al. Expression of CCR2, CCR5, and CXCR3 by CD4+ T cells is stable during a 2-year longitudinal study but varies widely between individuals. Journal of Neurovirology 2003; 9: 291-299.
10. Damas JK, Gullestad L, Aass H, et al. Enhanced gene expression of chemokines and their corresponding receptors in mononuclear blood cells in chronic heart failure - modulatory effect of intravenous immunoglobulin. Journal of the American College of Cardiology 2001; 38: 187-193.
11. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005; 128: 1887-1896.
12. Press R, Nennesmo I, Kouwenhoven M, et al. Dendritic cells in the cerebrospinal fluid and peripheral nerves in Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. Journal of Neuroimmunology 2005; 159: 165-176.
13. Kieseier BC, Tani M, Mahad D, et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies - a central role for IP-10. Brain 2002; 15: 571-577.
14. Lapointe BM, Herx LM, Gill V, Metz LM, Kubes P. IVIg therapy in brain inflammation: etiology-dependent differential effects on leucocyte recruitment. Brain 2004; 127: 2649-2656.
15. Dalakas MC. Inhibiting leukocyte recruitment to the brain by IVIg: is it relevant to the treatment of demyelinating CNS disorders? Brain 2004; 127: 2569-2571.
16. Vassilev TL, Kazatchkine MD, Van Huyen JP, et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999; 93: 3624-3631.
17. Amran D, Renz H, Lack G, Bradley K, Gelfand EW. Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clinical Immunology and Immunopathology 1994; 73: 180-186.
18. Aukrust P, Muller F, Nordoy I, Haug CJ, Froland SS. Modulation of lymphocyte and monocyte activity after intravenous immunoglobulin administration in vivo. Clinical and Experimental Immunology 1997; 107: 50-56.
19. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. Journal of Clinical Investigation 1996; 97: 865-869.